Associations - Topoisomerase II inhibitor

No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
No biomarker	Neuroblastoma	No biomarker	Neuroblastoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	pixantrone Sensitive: A1 - Approval pixantrone Sensitive : A1	pixantrone Sensitive: A1 - Approval pixantrone Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride Sensitive : A1	docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	non-pegylated liposomal doxorubicin Sensitive: A1 - Approval non-pegylated liposomal doxorubicin Sensitive : A1	non-pegylated liposomal doxorubicin Sensitive: A1 - Approval non-pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	idarubicin hydrochloride Sensitive: A1 - Approval idarubicin hydrochloride Sensitive : A1	idarubicin hydrochloride Sensitive: A1 - Approval idarubicin hydrochloride Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive: A2 - Guideline cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive : A2	cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive: A2 - Guideline cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive : A2

Topoisomerase II inhibitor

Topoisomerase II inhibitor

Associations(323)

Associations
(323)